Abstract. Recent studies have demonstrated an integration of recipient-derived progenitor cells into solid allografts with differentiation into parenchymal cells. Whether or to what extent this phenomenon influences allograft outcome has still to be elucidated. To detect epithelial chimerism tubular cells were harvested from sequential renal allograft biopsy samples by laser microdissection in 36 patients. Recipient-derived cells were detected by short-tandem repeat-based genotyping. In cases with gender-mismatched transplantation, chimerism was semiquantitatively evaluated by in situ hybridization for the Y-chromosome. Findings were correlated to different pathomechanisms of epithelial injury as well as to morphologic and clinical outcome. Epithelial chimerism was detectable as early as 8 d after transplantation and lasted for 8 yr.
Abstract. Recent studies have demonstrated an integration of recipient-derived progenitor cells into solid allografts with differentiation into parenchymal cells. Whether or to what extent this phenomenon influences allograft outcome has still to be elucidated. To detect epithelial chimerism tubular cells were harvested from sequential renal allograft biopsy samples by laser microdissection in 36 patients. Recipient-derived cells were detected by short-tandem repeat-based genotyping. In cases with gender-mismatched transplantation, chimerism was semiquantitatively evaluated by in situ hybridization for the Y-chromosome. Findings were correlated to different pathomechanisms of epithelial injury as well as to morphologic and clinical outcome. Epithelial chimerism was detectable as early as 8 d after transplantation and lasted for 8 yr. A total of 88% of the patients showed an epithelial chimerism; 72% had a stable chimerism in sequential biopsy samples. Evaluation of Y-chromosome by in situ hybridization revealed low percentages of chimerical tubular epithelial cells (2.4% to 6.6%). No correlation to morphology was found. Chimerism was detectable in inconspicuous protocol biopsy samples, cases of drug toxicity, and rejected allografts with and without chronic changes. No correlation was found to allograft function. Epithelial microchimerism is an early and persistent phenomenon after renal transplantation. There is no correlation to morphologic or functional outcome. Probably recipient-derived stem cells contribute in a minor fashion to tissue homeostasis, and cell turnover in renal allografts is predominantly enabled by donor cell renewal.
Immediately after transplantation, different nonimmunological and immunological mechanisms can damage the tubular epithelial cells of a renal allograft (1) (2) (3) . From observations in native kidneys, it is assumed that the source of regeneration after acute tubular damage are the viable epithelial cells at both ends of the damaged nephron segment, as well as other residual epithelial cells surviving along the tubular basement membrane (4, 5) . However, the definite origin of regenerating cells and the sequence of cellular recovery after acute tubular damage are not known exactly. On the basis of the mesenchymal-epithelial cell transdifferentiation during nephrogenesis, it might be also possible that interstitial multipotent, bone marrow-derived stem cells transdifferentiate into tubular epithelial cells under pathologic conditions (4,6 -8) .
In transplanted kidneys, recipient-derived pluripotent stem cells are thought to be an additional source for replacement of perished allograft cells. Recently, this could readily be demonstrated in animal models for tubular epithelial cells, stromal cells, glomerular podocytes, and endothelial cells undergoing damage from a variety of causes (6, 9) . In human renal allografts, recipient-derived endothelial cells were detected after vascular rejection (10) . Neointimal and interstitial mesenchymal cells of recipient origin have been described in transplants with chronic allograft nephropathy (11) . The chimeric coexistence of recipient-and donor-derived epithelial cells was recently demonstrated in other solid organ transplants (heart, lung, liver), indicating the tremendous plasticity of circulating recipient-derived precursor cells (12) (13) (14) (15) . From these recent studies, which were all based on relatively low numbers of cases (n Ͻ 15), it was assumed that cellular injury is the preceding event introducing intragraft chimerism after transplantation in humans. How different pathomechanisms and various types of cell damage induce intragraft microchimerism is not known. Furthermore, it is still a matter of debate whether recipient-derived intragraft microchimerism influences the immunresponse to the allograft in the sense of allograft accommodation, as was postulated by Medawar (16) four decades ago. Although the mechanism that leads to an integration of recipient-derived cells, transdifferentiation, or cell fusion is still under discussion, the effect of resulting chimerism on allograft outcome deserves study (17, 18) .
Because tubules are the major target of most mechanisms of acute cell damage in renal allografts, leading to tubular atrophy and chronic allograft nephropathy, we investigated chimerism of tubular epithelial cells. For this purpose, laser microdissection of tubular epithelial cells was combined with subsequent highly sensitive genotyping (DNA fingerprinting) by shorttandem repeat (STR)-PCR (12, 13) . This technique enables study of all allografts independent of gender mismatch. To further analyze the influence of different mechanisms of tubular injury on the induction of epithelial chimerism, and to assess whether epithelial chimerism has any effect on tubular regeneration after acute injury, we investigated sequential renal allograft biopsy samples from 36 patients with variable morphologic and functional outcome.
Materials and Methods

Cases
Sequential renal allograft biopsy samples from 36 patients were investigated. The first biopsy was performed within 3 mo after transplantation (8 to 91 d), and the second follow-up biopsy was performed at least 6 mo after transplantation (166 to 2910 d). All biopsy samples were histologically evaluated following the Banff '97 classification (1) . The patients were divided into seven subgroups according to different pathomechanisms that cause tubular epithelial damage (Table 1). Depending on the diagnosis made on the basis of the first biopsy sample and on whether, in the second biopsy sample, signs of chronic allograft nephropathy (tubular atrophy, interstitial fibrosis) were found, a patient was assigned to one of the following groups: (1) histopathologically unremarkable in first and second biopsy samples; (2) calcineurin inhibitor (CNI) toxicity in the first biopsy sample and chronic allograft nephropathy (CAN) in the follow-up sample; (3) CNI toxicity in the first biopsy sample and no CAN in the follow-up sample; (4) acute rejection in the first biopsy sample and CAN in the second sample; (5) acute rejection in the first biopsy sample and no CAN in the second sample; (6) Banff '97 borderline changes in the first biopsy sample and CAN in the second sample; and (7) Banff '97 borderline changes in the first biopsy sample and no CAN in the second sample. Additionally, in four patients, a baseline biopsy performed before implantation of the allograft was investigated as the first biopsy. Follow-up data concerning allograft function and immunosuppression protocols were retrieved from patient's files.
Laser Capture Microdissection and DNA Preparation
Sections (3 m) from formalin-fixed and paraffin-embedded allograft biopsy samples were mounted on glass slides coated with polyethylene foil. To exclude any contamination by infiltrating recipient leukocytes, an immunohistochemical stain for leukocyte common antigen (LCA/CD45; Dako, Hamburg, Germany) following a standard avidin-biotin complex (ABC) technique was performed ( Figure 1 ). Laser-based microdissection of cortical tubular epithelial cells was performed with the PALM Laser MicroBeam system (PALM, Wolfratshausen, Germany) (19) . At least 700 tubular epithelial cells were dissected from the renal cortex area in an immunohistochemically stained (anti CD45) section of each biopsy sample (n ϭ 72) ( Figure  2 ). After collecting the cells into the lid of a 0.5-ml reaction tube, the DNA was isolated by applying 25 l of proteinase K digestion buffer (50 mmol/L Tris, pH 8.1, 1 mmol/L EDTA, 0.5% Tween 20, 40 g/ml proteinase K) into the lid. The reaction tubes were incubated overnight at 55°C, and after denaturation at 94°C for 8 min, the lysate was used for subsequent PCR analysis.
STR-PCR
For detection of recipient-derived cells within the microdissected tubular epithelial cells, a PCR assay was applied that analyzes a highly polymorphic STR marker located within the human ␤-actin-related pseudogene, H-beta-Ac-psi2. This marker is also known as SE33 and contains a tetranucleotide repeat that displays considerable polymorphism and a high heterozygosity rate of up to 95% (20, 21) . To increase sensitivity for partially degraded DNA isolated from forma- lin-fixed, paraffin-embedded tissue, we used modified primers that reduce the length of the PCR products to fragments between 140 and 236 bp (13) . The amplification reaction was performed in a final volume of 25 l containing 22 nM of each primer, 0.5 units Hot Start Taq polymerase (Quiagen, Hilden, Germany), 1.5 mM MgCl 2 , 250 nM of dNTP, and up to 10 l DNA lysate. The reaction mixture was preheated at 95°C for 15 min, followed by 35 cycles at 94°C for 30 s, 56°C for 30 s, and 72°C for 1 min, with a final elongation step at 72°C for 10 min. The PCR products were analyzed with a capillary electrophoresis device (ABI310; Applied Biosystems, Darmstadt, Germany). One microliter of the PCR product was mixed with 0.5-l size standard (GeneScan350, Applied Biosystems, Darmstadt, Germany) and 12 l formamide. This mixture was heated for 2 min at 91°C and then immediately chilled on ice. Electrophoresis was performed following the manufacturer's instructions. Electropherograms displaying size and intensity of the PCR products were created by the software package supplied with the instrument (GeneScan310 analysis).
To identify recipient-derived cells within the microdissected tubular epithelia cells, first the allelotype of the recipient had to be revealed. This was performed by analogously analyzing a tissue specimen from the recipient, which had been archived before the renal transplantation. Analyzing an allograft biopsy sample without microdissection (total DNA extraction) supplied a mixture of recipient and donor allelotype. By subtracting the already known recipient allelotype from the mixed allelotype, the donor-specific alleles could readily be identified. The four preimplantation baseline biopsy samples served as negative controls. In 2 of the 72 investigated biopsy samples, insufficient DNA amounts were extracted from the microdissected cells.
Y-chromosome Hybridization Combined with Immunohistochemistry
From eight male patients who received a female renal allograft, sufficient biopsy material was available after STR analysis for additional Y-chromosome hybridization. For the detection of the Y-chromosome in the formalin-fixed and paraffin-embedded tissue, we applied a modified version of a previously described chromogenic in situ hybridization protocol (22) . The Y-chromosome hybridization with a specific centromere probe (Appligene-Oncor, Heidelberg, Germany) was combined with immunohistochemistry for a pan-cytokeratin antibody (clone KL-1; Beckman-Coulter Immunotech, Krefeld, Germany). In brief, paraffin was removed from sections of allograft biopsy samples and rehydrated. After incubation of primary antibody, the detection was done by a standard ABC-technique with BCIP/ NBT/INT (Dako) as chromogen producing a deep blue membrane stain of epithelial cells. Subsequently a DNA probe for the centromeric region of the Y-chromosome was incubated overnight (37°C) and detected by an optimized ABC technique (NenLifeSience). ACE (Dako) served as substrate developing a red to brown color.
For evaluation, the number of tubular epithelial cells showing a nuclear, spotlike brown signal per 500 tubular epithelial cells was recorded. Cells without a blue membrane stain (cytokeratin negative) were not counted, to exclude any contamination by graft infiltrating recipient-derived leukocytes. Female allografts in female recipients served as negative controls. Male nontransplanted, native kidneys served as positive controls.
Statistical Analyses
SPSS statistical software version 10.0 (SPSS, Chicago, IL) was used for statistical analyses. Correlation between a persistent or discontinuously present/absent epithelial chimerism and allograft function was done by Wilcoxon test for paired data and the Mann-Whitney test for unpaired data. Allograft function was determined by calculation of quotient of the maximal calculated creatinine clearance within the first 6 mo after transplantation and the calculated creatinine clearance at 18 mo after transplantation. The creatinine clearance was calculated from the respective serum creatinine levels applying the formula provided by Cockcroft and Gault (23) . Results were considered significant when the P value was less than 0.05.
Results
STR-PCR after Laser Microdissection
Thirty-two (88%) of 36 investigated patients showed an intragraft epithelial microchimerism in at least one of their biopsy samples ( Figure 3, Table 2 ). In 26 of these patients (72%), a stable chimerism (i.e., first and second biopsy chimeric) of tubular epithelial cells was found. In four patients (11.1%), no microchimerism was detectable in any of their sequential biopsy samples (Figure 4) . In three cases, the first biopsy showed no microchimerism, whereas the second did. Just in one patient, the opposite constellation was found, with chimerism in the first biopsy sample only.
An epithelial microchimerism was detectable as early as 8 d after transplantation. Chimeric cells were found, too, in a biopsy sample taken 8 yr after transplantation. In our cohort, this was the longest time period between two sequential biopsies available and demonstrating a stable (i.e., first and second biopsy chimeric) microchimerism. As expected, none of the preimplantation biopsy samples revealed an epithelial microchimerism.
Correlation of Epithelial Microchimerism with Biopsy Pathology
For correlation of epithelial microchimerism, the patients with baseline biopsy findings at first biopsy were grouped according to the diagnosis of their second biopsy (Table 3 ). All four patients from the first group (histopathologically unremarkable in first and second biopsy samples) and all three patients from the second group (CNI toxicity in the first biopsy and CAN in the follow-up biopsy samples) developed an intragraft microchimerism. Within the third group (CNI toxicity in first biopsy sample and no CAN in second biopsy sample), one of two patients was chimeric. In patients with acute rejection (group 4) in the first and CAN in the second biopsy samples, 93% (13 of 14) of the patients showed an epithelial microchimerism. In 80% of the patients (four of five) of the fifth group (acute rejection in first and no CAN in second), a microchimerism was found. All patients from group 6 (Banff '97 borderline changes in first and CAN in second), and four of five patients from group 7 (Banff '97 borderline changes in first and no CAN in second) were chimeric.
Correlation of Epithelial Microchimerism with Immunosuppression Protocols
Most of the patients (n ϭ 15) received tacrolimus and corticosteroids as a maintenance immunosuppressive therapy. Analysis of samples taken via biopsy revealed 11 of these patients to be chimeric, 1 only in the second biopsy sample; 3 had no chimerism at all. Only two patients received cyclosporine A and corticosteroids, one being stably chimeric and the other chimeric only in the second biopsy sample. One patient with mycophenolatmofetil who was receiving corticosteroid therapy was chimeric in both biopsy samples. The rest of the investigated patients (n ϭ 16) had a triple immunosuppression comprising variable combinations of tacrolimus or cyclosporine A with corticosteroids and mycophenolatmofetil or azathioprine. The majority of these patients (n ϭ 11) had a stable chimerism in both biopsy samples (Table 4) .
Y-chromosome In Situ Hybridization
After laser microdissection and STR-PCR analysis from eight male patients (11 samples) who received a female allograft, sufficient material was available for Y-chromosome in situ hybridization. Without exception, these samples all showed an epithelial microchimerism in STR-PCR analysis, as well as in the Y-chromosome in situ hybridization approach ( Figure 5 ). All samples with suitable Y-chromosome in situ hybridization showed morphologic signs of acute cellular rejection (Table 5) .
Quantitative Therefore, we adjusted the cell count from the allografts by a factor of three, to 2.4% to 6.6% chimeric tubular epithelial cells (6) . From three patients (patients 7, 23, and 24), Y-chromosome in situ hybridization results for both sequential samples were available. In one patient (patient 23), the number of chimeric cells increased, whereas it decreased in two (patients 7 and 24) over time. In the same slides, frequently nuclei with a Ychromosome signal were detectable within glomerular tufts, but only in single cells at the endothelial site of small-and medium-size arteries. Without performing simultaneous immunohistochemical phenotyping, it was impossible to clearly discriminate these cells on a purely morphologic basis from invading monocytes or leukocytes.
Chimerism and Outcome
For 33 patients, follow-up data concerning the calculated creatinine clearance 18 mo after transplantation were available. Twenty-nine of these patients showed a decrease in their creatinine clearance, two an increase, and two returned to dialysis. A total of 21 of the 33 patients had a persistent epithelial chimerism. The quotient of best creatinine clearance in the first 6 mo after transplantation and creatinine clearance at 18 mo ranged within these patients with persistent chimerism from 0.94 and 4.6 (mean 1.61, SD 0.84). Ten patients had no (n ϭ 4) or a discontinuous (n ϭ 6) epithelial chimerism with a creatinine clearance quotient between 0.71 and 1.65 (mean 1.21, SD 0.33). No statistical significant correlation between chimerism and allograft function at 18 mo after transplantation was found (P Ͼ 0.05).
Discussion
Currently, the classic paradigm of stem cell differentiation restricted to its organ-specific lineage is challenged by intrigu- ing findings suggesting that adult stem cells, including hematopoietic stem cells, retain a previously unrecognized degree of developmental plasticity that allows them to differentiate across boundaries of lineage, tissue, and germ layer (24 -27) . Numerous studies suggest that tissue injury is the preceding and stimulating event recruiting circulating stem cells into various solid organs, subsequently transdifferentiating into tissue-specific cells (reviewed in (24)). However, the involved mechanisms are not fully understood. Solid organ transplants in particular suffer severe tissue damage, at least during their harvest, as well as quite frequent numerous additional insults during their early posttransplant period. Therefore, the finding that recipient-derived stem cells settle into the graft and transdifferentiate into organ-specific cells created tremendous hope that this can be the source for organ restitution and unlimited long-term graft function. According to the results presented here from a large series of study of renal allograft biopsy samples, it is unlikely that the presence of recipient-derived epithelial cells (i.e., intragraft microchimerism) has any influence on graft outcome, either with regard to morphology (onset of chronic tubulointerstitial damage) or to allograft function (decrease in creatinine clearance). Although recipient-derived epithelial cells were found very early after transplantation in 88% of the patients, which persisted in the majority of these patients for a long time, no obvious correlation to a specific mechanism of epithelial injury was found. Moreover, even cases lacking morphologically visible signs of early cell damage became rapidly chimeric after transplantation. A possible explanation might be that all allografts will suffer some diffuse epithelial damage during organ harvest and reperfusion. However, we looked in our collective for allografts after living donation (n ϭ 2). Both showed a stable chimerism in their sequential biopsies (data not shown). Although others were able to show a correlation between the extent of tissue damage and an increased chimerism in various solid organ transplants (10,12,13,28,29), we were not able to demonstrate this for tubular epithelial cells in renal allografts.
In two of our cases, investigated semiquantitatively by Ychromosome in situ hybridization, we observed a decrease of chimeric cells after initial acute cellular rejection, whereas in a third case, microchimerism increased in the subsequent biopsy.
In the lung, a positive correlation between chimerism and degree of tissue damage was demonstrated for the epithelial cells in bronchi and peribronchial glands, while it was lacking for chimeric type II pneumocytes (13) . These findings might indicate that in different types of allografts, different cell types are variably replaced by recipient-derived stem cells after initial cellular damage. According to our findings and those of others, a basal microchimerism promptly established after transplantation remains stable, qualitatively and more or less quantitatively, in the long-term course of the majority of allografts (6, 13, 14, 30, 31) .
This observation is in contrast to the hypothesis of Medawar (16) that adaptation and tolerance in allografts may be the result of gradual replacement of the cells of the donor by those of the recipient in the posttransplant course. Furthermore, a recent study in liver allografts, which more frequently show permanent tolerance than kidney allografts, revealed similar endothelial cell chimerism in both tolerant and nontolerant patients, leading to the conclusion that chimerism has nothing to do with the induction of clinical tolerance (32) . From our 26 constantly chimeric patients, 62% (16 of 26) developed morphologic signs of chronic rejection, and 4 even returned to dialysis 18 mo after transplantation-events one would not expect from accommodated allografts.
Obviously, the majority of solid organ allografts incorporate recipient-derived stem cells very early after transplantation, but without inducing tolerance (6, 13, 14, 30, 31) . Furthermore, recipient-derived precursor cells do not represent an inexhaustible source for tissue regeneration, and they appear unable to prevent long-term deterioration of an allograft. In the kidney, these cells might even contribute to chronic irreversible interstitial and vascular scarring (11) . Otherwise, in our collective, patients showing any chimerism had a favorable morphologic outcome, i.e., no chronic allograft nephropathy in the follow-up biopsy.
Although our study contributes to the evidence that adult stem cells can transdifferentiate to mature, organ-specific cells, it is not able to demonstrate any clinical relevance for renal allografts at present. To exploit the therapeutic capacity of recruitment of pluripotent stem cells to damaged organs (24) , more must be known about the biology of these enigmatic cells.
